INDIGO Kits and Services
The emergence of liver toxicity is major reason for the termination of clinical drug trials, as well as post-market withdrawal fo approved drugs. The assay kit for in vitro screening of drug-induced hepatotoxicity allows researchers to rapidly identify those compounds that induce liver toxicity. The kit utilizes upcyte® hepatocytes, prepared using our proprietary CryoMiteTM process, which yields high viability post-thaw and provides the convenience of immediately dispensing cells into assay plates. This all-inclusive assay kit allows users to bring processes previously available only as contract screening services into their own labs. Learn more.
Determining if a drug candidate will have incidental interactions with P-Glycoprotein (P-gp, aka MDR-1, or ABCB1) is an important component of the safety assessment process. A drug that is either a substrate or inhibitor of MDR1 transporter activity can significantly alter the rate of absorption, distribution, metabolic conversion, and eventual excretion of co-administered drugs, thereby shifting their therapeutic effects and toxicologic profiles. Because of this, assessing a new drug's potency as an interactor with P-gp, and thus its potential liability for inducing downstream drug-drug interactions, is mandated by the FDA. Our all-inclusive assay kit for the assessment of MDR1 drug interaction allows users to rapidly assess drug candidates as either inhibitors, substrates, or non-substrates of P-gp, and make critical decisions about potential drug candidates with confidence.Learn more.
Assessing drug-induced changes in the expression of Cytochrome P450 (CYP) genes provides a reliable predictive indicator of altered metabolic activity in vivo. It is estimated that CYPs are involved in 70% to 80% of drugs currently on the market, making understanding their metabolic actions crucial to the drug development process. Our gene expression assay kit provides optimized reagents for the culturing and treatment of upcyte® hepatocytes to assess drug-induced changed in the expression of seven clinically relevant CYPs: CYP3A4, CYP1A1, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2E1. Learn more.